Shukra Pharmaceuticals (524632) Q3 24/25 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and nine months ended 31st December 2024, following audit committee review.

• Appointed Mr. Jay Gandhi as Internal Auditor and Ms. Shilpa Shah as Secretarial Auditor for FY 2024-25.

Financial highlights

• Revenue from operations for the quarter ended 31st Dec 2024 was ₹1,058.43 lakhs, up from ₹555.52 lakhs in the previous quarter.

• Net profit for the quarter was ₹316.44 lakhs, compared to ₹53.89 lakhs in the previous quarter and ₹942.18 lakhs in the same quarter last year.

• For the nine months ended 31st Dec 2024, revenue was ₹6,368.90 lakhs and net profit was ₹418.87 lakhs.

• Basic and diluted EPS for the quarter were ₹0.72, compared to ₹0.12 in the previous quarter.

Outlook and guidance

• Internal and secretarial audits for FY 2024-25 are expected to enhance compliance and internal controls.